Search This Blog

Tuesday, September 8, 2026

FDA accepts Apnimed’s Oxnimbi (AD109) NDA, sets February 28, 2027 PDUFA target date

 

  • Apnimed reports second-quarter 2026 results, highlighting strengthened cash position following its recent $220.8 million IPO.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)